(AVNS) Avanos Medical - NYSE
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 1.171m USD | Total Return: 93.5% in 12m
Avg Turnover: 22.8M
EPS Trend: -64.5%
Qual. Beats: 1
Rev. Trend: 87.7%
Qual. Beats: 4
Warnings
Interest Coverage Ratio -8.1 is critical
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
Avanos Medical, Inc. (AVNS) is a medical technology firm specializing in digestive health and non-opioid pain management solutions. Its portfolio includes enteral feeding tubes, neonatal feeding systems, and cold compression therapy devices. The company operates globally, selling directly to healthcare providers and through wholesale distribution networks.
The medical device sector is characterized by high barriers to entry due to stringent regulatory approval processes and established clinical integration. Avanos utilizes a recurring revenue model by providing specialized consumables, such as feeding tubes, that require regular replacement in clinical settings.
The company also focuses on interventional pain therapies, utilizing radiofrequency ablation technology to treat chronic conditions without the use of opioids. For deeper insights into these market segments, ValueRay provides comprehensive analytical tools. Founded in 2014 and headquartered in Georgia, Avanos was previously known as Halyard Health before its rebranding in 2018.
- Market share growth in enteral feeding products drives core digestive health revenue
- Shift toward non-opioid surgical pain solutions impacts surgical recovery segment margins
- Execution of multi-year cost transformation program influences operating income and profitability
- Strategic divestitures of non-core assets reshape the long-term medical device portfolio
- Hospital elective procedure volumes dictate demand for interventional pain and RFA products
| Net Income: -69.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -9.58 > 1.0 |
| NWC/Revenue: 27.07% < 20% (prev 31.22%; Δ -4.15% < -1%) |
| CFO/TA 0.03 > 3% & CFO 36.7m > Net Income -69.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.48 > 1.5 & < 3 |
| Outstanding Shares: last quarter (46.4m) vs 12m ago -0.85% < -2% |
| Gross Margin: 48.55% > 18% (prev 54.79%; Δ -6.23% > 0.5%) |
| Asset Turnover: 66.35% > 50% (prev 62.21%; Δ 4.14% > 0%) |
| Interest Coverage Ratio: -8.06 > 6 (EBIT TTM -58.0m / Interest Expense TTM 7.20m) |
| A: 0.18 (Total Current Assets 325.0m - Total Current Liabilities 131.2m) / Total Assets 1.05b |
| B: -0.74 (Retained Earnings -774.8m / Total Assets 1.05b) |
| C: -0.05 (EBIT TTM -58.0m / Avg Total Assets 1.08b) |
| D: 2.92 (Book Value of Equity 782.1m / Total Liabilities 268.0m) |
| Altman-Z'' = 1.51 = BB |
| DSRI: 0.95 (Receivables 103.0m/104.8m, Revenue 715.9m/689.2m) |
| GMI: 1.13 (GM 54.79% / 48.55%) |
| AQI: 0.99 (AQ_t 0.55 / AQ_t-1 0.55) |
| SGI: 1.04 (Revenue 715.9m / 689.2m) |
| TATA: -0.10 (NI -69.4m - CFO 36.7m) / TA 1.05b) |
| Beneish M = -2.94 (Cap -4..+1) = A |
As of June 11, 2026, the stock is trading at USD 24.98 with a total of 629,211 shares traded.
Over the past week, the price has changed by +0.00%,
over one month by +0.69%,
over three months by +90.54% and
over the past year by +93.49%.
Avanos Medical has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold AVNS.
- StrongBuy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14 | -44% |
P/E Forward = 30.6748
P/S = 1.6352
P/B = 1.4998
Revenue TTM = 715.9m USD
EBIT TTM = -58.0m USD
EBITDA TTM = -18.5m USD
Long Term Debt = 87.3m USD (from longTermDebt, last quarter)
Short Term Debt = 21.3m USD (from shortTermDebt, last quarter)
Debt = 178.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 40.2m
Net Debt = 113.0m USD (calculated: Debt 178.6m - CCE 65.6m)
Enterprise Value = 1.28b USD (1.17b + Debt 178.6m - CCE 65.6m)
Interest Coverage Ratio = -8.06 (Ebit TTM -58.0m / Interest Expense TTM 7.20m)
EV/FCF = 171.1x (Enterprise Value 1.28b / FCF TTM 7.50m)
FCF Yield = 0.58% (FCF TTM 7.50m / Enterprise Value 1.28b)
FCF Margin = 1.05% (FCF TTM 7.50m / Revenue TTM 715.9m)
Net Margin = -9.69% (Net Income TTM -69.4m / Revenue TTM 715.9m)
Gross Margin = 48.55% ((Revenue TTM 715.9m - Cost of Revenue TTM 368.3m) / Revenue TTM)
Gross Margin QoQ = 48.52% (prev 47.54%)
Tobins Q-Ratio = 1.22 (Enterprise Value 1.28b / Total Assets 1.05b)
Interest Expense / Debt = 4.03% (Interest Expense 7.20m / Debt 178.6m)
Taxrate = 32.89% (2.50m / 7.60m)
NOPAT = -38.9m (EBIT -58.0m * (1 - 32.89%)) [loss with tax shield]
Current Ratio = 2.48 (Total Current Assets 325.0m / Total Current Liabilities 131.2m)
Debt / Equity = 0.23 (Debt 178.6m / totalStockholderEquity, last quarter 782.1m)
Debt / EBITDA = -6.11 (negative EBITDA) (Net Debt 113.0m / EBITDA -18.5m)
Debt / FCF = 15.07 (Net Debt 113.0m / FCF TTM 7.50m)
Total Stockholder Equity = 778.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -6.43% (Net Income -69.4m / Total Assets 1.05b)
RoE = -8.91% (Net Income TTM -69.4m / Total Stockholder Equity 778.6m)
RoCE = -6.70% (EBIT -58.0m / Capital Employed (Equity 778.6m + L.T.Debt 87.3m))
RoIC = -4.30% (negative operating profit) (NOPAT -38.9m / Invested Capital 904.4m)
WACC = 9.30% (E(1.17b)/V(1.35b) * Re(10.31%) + D(178.6m)/V(1.35b) * Rd(4.03%) * (1-Tc(0.33)))
Discount Rate = 10.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 9.43 | Cagr: -0.19%
[DCF] Terminal Value 69.61% ; FCFF base≈50.1m ; Y1≈43.9m ; Y5≈35.5m
[DCF] Fair Price = 8.10 (EV 492.5m - Net Debt 113.0m = Equity 379.5m / Shares 46.8m; r=9.30% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -64.48 | EPS CAGR: -10.72% | SUE: 2.09 | # QB: 1
Revenue Correlation: 87.65 | Revenue CAGR: 1.66% | SUE: 2.21 | # QB: 4
EPS current Quarter (2026-06-30): EPS=0.16 | Chg30d=+0.00% | Revisions=-20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.33 | Chg30d=+0.00% | Revisions=+20% | Analysts=1
EPS current Year (2026-12-31): EPS=1.00 | Chg30d=+0.00% | Revisions=+20% | GrowthEPS=+6.4% | GrowthRev=+1.2%
EPS next Year (2027-12-31): EPS=1.25 | Chg30d=+0.00% | Revisions=-20% | GrowthEPS=+25.0% | GrowthRev=+4.2%